Clinical Trial Update: A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating BH-30236 in patients with relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes. The study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• BH-30236

Snippet

Sponsor: BlossomHill Therapeutics | Conditions: Leukemia, Leukemia, Myeloid | Phase 1 | Status: RECRUITING